Structure of the Chemokine Receptor CXCR3
趋化因子受体 CXCR3 的结构
基本信息
- 批准号:8773139
- 负责人:
- 金额:$ 24.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AMD3100AffinityAgonistAutoimmune DiseasesAutologous Bone Marrow TransplantationBindingBone MarrowCCR5 geneCD34 geneCD8B1 geneCXCL10 geneCXCL11 geneCXCL12 geneCXCL9 geneCXCR3 geneCXCR4 ReceptorsCXCR4 geneCellsChemotaxisCollaborationsComplexCrystallizationCrystallographyCytotoxic T-LymphocytesDataData CollectionDiseaseDoxepinDrug TargetingEquipmentEscherichia coliFDA approvedFoundationsFunctional disorderG-Protein-Coupled ReceptorsGoalsGraft RejectionGrowthHIVHIV-1HealthHematopoieticHematopoietic stem cellsHistamine H1 ReceptorsHomeostasisHumanImmune responseImmunologic AdjuvantsInfectionInflammatoryInterferonsLearningLettersLigandsLocationMalignant NeoplasmsMembrane ProteinsMetabolismMetastatic toMuramidaseNatural ImmunityNetherlandsPharmaceutical ChemistryPhasePhase II Clinical TrialsPhotonsPostdoctoral FellowPropertyProteinsPsoriasisRecruitment ActivityResearch InstituteRoleScientistSourceStructureSystemT-LymphocyteTechnologyTherapeuticTissuesadaptive immunitybasebiophysical propertiescell motilitychemokinechemokine receptordesignexperiencegraft vs host diseaseimmune functionin vivointerestmedical schoolsprotein-tyrosine sulfotransferasepublic health relevancereceptorreceptor functionreconstitutionsmall moleculestructural biologytherapeutic target
项目摘要
DESCRIPTION (provided by applicant): G-protein coupled receptors (GPCRs) have many functions in human health and disease. About 30% of FDA approved drugs target these types of receptors. Chemokine receptors belong to a subfamily of GPCRs, are activated by small proteins of 8 kDa, and are involved in homeostasis and the immune response. CXCR3 is one of 20 chemokine receptors, is activated by three chemokines, CXCL9, 10, and 11, and is involved in recruiting CD4+ type-1 helper (Th1) or CD8+ cytotoxic T-cells to inflammatory tissues to initiate an appropriate immune response. These three chemokines are differentially regulated and, therefore, do not have redundant roles in vivo although they compete for binding to CXCR3 in cellular studies. These chemokines and CXCR3 are also involved in various autoimmune diseases, transplant rejection and graft versus host disease, specific infections, and cancer. Therefore, these chemokines and CXCR3 are attractive therapeutic targets for a number of diseases. One compound (AMG487) failed Phase II clinical trials for psoriasis, presumably due to its in vivo metabolism. The main goal in this application is to use structural biology of CXCR3 complexed to a small molecule antagonist to provide the foundation for the design of other antagonists with the optimum properties for a therapeutic. We are also interested in a more fundamental question: how do chemokines bind their receptors? Finding an answer to this question is beyond the scope of this proposal, but based on previous experience to purify a stable chemokine-receptor complex, we intend to explore creating a clone in P. pastoris expressing CXCR3, each of its chemokine agonists, and two other proteins that result in increased the affinity and stability between CXCR3 and each of its chemokine agonists.
描述(由申请人提供):G蛋白偶联受体(GPCR)在人类健康和疾病中具有许多功能。大约30%的FDA批准的药物靶向这些类型的受体。 趋化因子受体属于GPCR的亚家族,由8 kDa的小蛋白激活,并且参与稳态和免疫应答。 CXCR 3是20种趋化因子受体之一,由三种趋化因子CXCL 9、10和11激活,并参与将CD 4 + 1型辅助细胞(Th 1)或CD 8+细胞毒性T细胞募集到炎性组织以启动适当的免疫应答。这三种趋化因子是差异调节的,因此,虽然它们在细胞研究中竞争与CXCR 3的结合,但在体内没有多余的作用。这些趋化因子和CXCR 3也参与各种自身免疫性疾病、移植排斥和移植物抗宿主病、特异性感染和癌症。 因此,这些趋化因子和CXCR 3是许多疾病的有吸引力的治疗靶点。一种化合物(AMG 487)在银屑病II期临床试验中失败,可能是由于其体内代谢。 本申请的主要目的是利用与小分子拮抗剂复合的CXCR 3的结构生物学,为设计具有最佳治疗性质的其他拮抗剂提供基础。我们还对一个更基本的问题感兴趣:趋化因子如何结合它们的受体?找到这个问题的答案超出了这个提议的范围,但是基于先前纯化稳定的趋化因子-受体复合物的经验,我们打算探索在巴斯德毕赤酵母中创建表达CXCR 3、其每种趋化因子激动剂以及导致CXCR 3与其每种趋化因子激动剂之间的亲和力和稳定性增加的另外两种蛋白质的克隆。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ELIAS LOLIS其他文献
ELIAS LOLIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ELIAS LOLIS', 18)}}的其他基金
Crystal Structures of CXCR4 complexed to CXCL12
CXCR4 与 CXCL12 复合的晶体结构
- 批准号:
7977990 - 财政年份:2010
- 资助金额:
$ 24.98万 - 项目类别:
Crystal Structures of CXCR4 complexed to CXCL12
CXCR4 与 CXCL12 复合的晶体结构
- 批准号:
8143383 - 财政年份:2010
- 资助金额:
$ 24.98万 - 项目类别:
Regulation of CXCR4 by cognate and non-cognate ligands
同源和非同源配体对 CXCR4 的调节
- 批准号:
8416439 - 财政年份:2009
- 资助金额:
$ 24.98万 - 项目类别:
Regulation of CXCR4 by cognate and non-cognate ligands
同源和非同源配体对 CXCR4 的调节
- 批准号:
7765573 - 财政年份:2009
- 资助金额:
$ 24.98万 - 项目类别:
Regulation of CXCR4 by cognate and non-cognate ligands
同源和非同源配体对 CXCR4 的调节
- 批准号:
8014942 - 财政年份:2009
- 资助金额:
$ 24.98万 - 项目类别:
Regulation of CXCR4 by cognate and non-cognate ligands
同源和非同源配体对 CXCR4 的调节
- 批准号:
7635937 - 财政年份:2009
- 资助金额:
$ 24.98万 - 项目类别:
相似海外基金
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10412227 - 财政年份:2022
- 资助金额:
$ 24.98万 - 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10610473 - 财政年份:2022
- 资助金额:
$ 24.98万 - 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
- 批准号:
10799162 - 财政年份:2022
- 资助金额:
$ 24.98万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6639179 - 财政年份:2001
- 资助金额:
$ 24.98万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6724797 - 财政年份:2001
- 资助金额:
$ 24.98万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6636512 - 财政年份:2001
- 资助金额:
$ 24.98万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6326889 - 财政年份:2001
- 资助金额:
$ 24.98万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6266928 - 财政年份:2001
- 资助金额:
$ 24.98万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6539099 - 财政年份:2001
- 资助金额:
$ 24.98万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6520329 - 财政年份:2001
- 资助金额:
$ 24.98万 - 项目类别: